                         SEQUENCE LISTING

<110>  Magenta Therapeutics, Inc.
 
<120>  DOSING REGIMENS FOR HEMATOPOIETIC STEM CELL MOBILIZATION FOR STEM CELL TRANSPLANTS IN MULTIPLE MYELOMA PATIENTS	

<130>  MGA-010WO

<140>  PCT/US2022/020510
<141>  2022-03-16

<150>  63/161,882
<151>  2021-03-16

<150>  63/196,610
<151>  2021-06-03

<150>  63/273,856
<151>  2021-10-29

<160>  4     
<170>  PatentIn version 3.5

<210>  1
<211>  73
<212>  PRT
<213>  Homo sapiens

<400>  1

Ala Pro Leu Ala Thr Glu Leu Arg Cys Gln Cys Leu Gln Thr Leu Gln 
1               5                   10                  15      


Gly Ile His Leu Lys Asn Ile Gln Ser Val Lys Val Lys Ser Pro Gly 
            20                  25                  30          


Pro His Cys Ala Gln Thr Glu Val Ile Ala Thr Leu Lys Asn Gly Gln 
        35                  40                  45              


Lys Ala Cys Leu Asn Pro Ala Ser Pro Met Val Lys Lys Ile Ile Glu 
    50                  55                  60                  


Lys Met Leu Lys Asn Gly Lys Ser Asn 
65                  70              


<210>  2
<211>  69
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  2

Thr Glu Leu Arg Cys Gln Cys Leu Gln Thr Leu Gln Gly Ile His Leu 
1               5                   10                  15      


Lys Asn Ile Gln Ser Val Lys Val Lys Ser Pro Gly Pro His Cys Ala 
            20                  25                  30          


Gln Thr Glu Val Ile Ala Thr Leu Lys Asn Gly Gln Lys Ala Cys Leu 
        35                  40                  45              


Asn Pro Ala Ser Pro Met Val Lys Lys Ile Ile Glu Lys Met Leu Lys 
    50                  55                  60                  


Asn Gly Lys Ser Asn 
65                  


<210>  3
<211>  73
<212>  PRT
<213>  Homo sapiens

<400>  3

Ala Pro Leu Ala Thr Glu Leu Arg Cys Gln Cys Leu Gln Thr Leu Gln 
1               5                   10                  15      


Gly Ile His Leu Lys Asn Ile Gln Ser Val Lys Val Lys Ser Pro Gly 
            20                  25                  30          


Pro His Cys Ala Gln Thr Glu Val Ile Ala Thr Leu Lys Asn Gly Gln 
        35                  40                  45              


Lys Ala Cys Leu Asn Pro Ala Ser Pro Met Val Lys Lys Ile Ile Glu 
    50                  55                  60                  


Lys Met Leu Lys Asp Gly Lys Ser Asn 
65                  70              


<210>  4
<211>  69
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic Construct

<400>  4

Thr Glu Leu Arg Cys Gln Cys Leu Gln Thr Leu Gln Gly Ile His Leu 
1               5                   10                  15      


Lys Asn Ile Gln Ser Val Lys Val Lys Ser Pro Gly Pro His Cys Ala 
            20                  25                  30          


Gln Thr Glu Val Ile Ala Thr Leu Lys Asn Gly Gln Lys Ala Cys Leu 
        35                  40                  45              


Asn Pro Ala Ser Pro Met Val Lys Lys Ile Ile Glu Lys Met Leu Lys 
    50                  55                  60                  


Asp Gly Lys Ser Asn 
65                  


